BridgeMD
Phase 1b/2a Study to Evaluate Alnuctamab in Combination with Mezigdomide in Relapsed and/or Refractory Multiple Myeloma.
EU CTIS ID: 2023-504367-16-00
What this study is testing
To determine the safety and tolerability of alnuctamab in combination with mezigdomide in participants with RRMM (primary - all phases). To determine the recommended Phase 2 dose (RP2D) and schedule of mezigdomide when administered in combination with alnuctamab in participants with RRMM (Phase 1b only). To evaluate the preliminary efficacy of alnuctamab in combination with mezigdomide in comparison to alnuctamab monotherapy in participants with RRMM (Phase 2a only).
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Age ≥ 18 with history of RRMM treated with ≥ 3 prior lines of antimyeloma therapy (Part A) or 1 to 3 prior lines of anti-myeloma therapy (Parts B and C).
- Measurable MM by central laboratory.
- Eastern Cooperative Oncology Group performance status of 0 to 1.
- Adherence to contraception requirements.
You likely can't join if
- Prior treatment with mezigdomide or alnuctamab.
- Other exclusion criteria can be found in the protocol.
The study team makes the final eligibility decision.
Where it's taking place
- United States
- Israel
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include United States; Israel. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.